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Cost effectiveness of ward based non-invasive ventilation
for acute exacerbations of chronic obstructive pulmonary
disease: economic analysis of randomised controlled trial
P K Plant, J L Owen, S Parrott, M W Elliott
Abstract
Objective To evaluate the cost effectiveness of
standard treatment with and without the addition of
ward based non-invasive ventilation in patients
admitted to hospital with an acute exacerbation of
chronic obstructive pulmonary disease.
Design Incremental cost effectiveness analysis of a
randomised controlled trial.
Setting Medical wards in 14 hospitals in the United
Kingdom.
Participants The trial comprised 236 patients
admitted to hospital with an acute exacerbation of
chronic obstructive pulmonary disease and mild to
moderate acidosis (pH 7.25-7.35) secondary to
respiratory failure. The economic analysis compared
the costs of treatment that these patients received
after randomisation.
Main outcome measure Incremental cost per
in-hospital death.
Results 24/118 died in the group receiving standard
treatment and 12/118 in the group receiving
non-invasive ventilation (P=0.05). Allocation to the
group receiving non-invasive ventilation was
associated with a reduction in costs of £49 362
($78 741; €73 109), mainly through reduced use of
intensive care units. The incremental cost effectiveness
ratio was − £645 per death avoided (95% confidence
interval − £2310 to £386), indicating a dominant
(more effective and less costly) strategy. Modelling of
these data indicates that a typical UK hospital
providing a non-invasive ventilation service will avoid
six deaths and three to nine admissions to intensive
care units per year, with an associated cost reduction
of £12 000-53 000 per year.
Conclusions Non-invasive ventilation is a highly cost
effective treatment that both reduced total costs and
improved mortality in hospital.
Introduction
Non-invasive ventilation in the intensive care unit has
been shown to reduce the need for intubation and the
in-hospital mortality associated with severe exacerba-
tions of chronic obstructive pulmonary disease.1–4 It is
also feasible and effective in the ward environment for
patients who are less severely ill. In a randomised con-
trolled trial with 14 participating centres we have
shown that non-invasive ventilation reduces the need
for intubation by 44% and in-hospital mortality by
50%.5 These results were, however, obtained at a price
that included the training of staff, the provision of
equipment, and the consumption of additional nursing
time.6 For non-invasive ventilation to be implemented
widely it is necessary to show that the technique is cost
effective in the context of the trial and also to model
costs in a real life scenario. We report a health
economic analysis of the randomised controlled trial,
which models the costs and effects of providing a non-
invasive ventilation service in a typical hospital in the
United Kingdom for patients with chronic obstructive
pulmonary disease and mild to moderate respiratory
acidosis.
Subjects and methods
The economic analysis was an incremental cost
effectiveness analysis,7 performed alongside a 14
centre randomised controlled trial (figure), which com-
pared standard medical treatment (see box) with
standard treatment plus non-invasive ventilation (see
box) in patients admitted to hospital with an exacerba-
tion of chronic obstructive pulmonary disease, respira-
tory acidosis (pH 7.25-7.35), and a respiratory rate
greater than 23 breaths per minute.5 The nurses
administered non-invasive ventilation according to a
predefined protocol until the morning of a patient’s
fourth day. The principal clinical outcomes were the
need for intubation, using predefined criteria
(pH< 7.20; pH 7.20-7.25 on two occasions 1 hour
apart; hypercapnic coma; Pao2 < 6 kPa despite
maximum tolerated Fio2; cardiorespiratory arrest) and
in-hospital mortality.5 Once a patient met the criterion
“need for intubation,” the attending doctor was free to
offer ventilatory support (invasively or non-invasively)
at his or her discretion. The primary outcome measure
for the economic analysis was mortality in hospital. We
conducted the economic evaluation from the perspec-
tive of the NHS and hence included only direct costs to
the hospitals providing acute care.
Costs
We identified and valued three categories of costs—for
wards, non-invasive ventilation, and intensive care
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units. We estimated the valuations used for the
financial year 1997-8 and derived them from the units
participating in the study, using a bottom up approach.
Ward costs—Ward costs consisted of costs for
nursing staff, pharmacy, and overheads such as
heating, lighting, and costs of buildings. Nursing staff
provided non-invasive ventilation for the first three
days of the admission.We identified additional nursing
time that was attributable to non-invasive ventilation by
using a log kept at the end of the bed for the first five
days of the admission, on which duration of activity
and the seniority (grade) of the nurse were recorded.
We calculated the cost of nursing by using the cost of a
bed day on each ward, multiplied by the length of stay,
and by adding the extra cost of nursing that we identi-
fied from the log. We derived pharmacy costs from the
standard treatment protocol and allocated these in
relation to length of stay and valued from the British
National Formulary (March 1997). Each finance depart-
ment provided daily overhead costs and allocated
these in relation to length of stay. In this incremental
analysis we assumed costs for investigations and wards
to be equal in the two study groups.
Costs of non-invasive ventilation—The costs of
non-invasive ventilation included the cost of the initial
purchase of the ventilator and selection of masks,
replacement of consumables, annual servicing, and
training of staff.We treated the initial purchase as a capi-
tal purchase with three year and two year life spans for
the ventilators and masks, respectively. We applied a dis-
count rate of 5%.8 Masks, tubing, connectors, and head-
gear were replaced after 10 patients. We obtained the
costs of cleaning and annual servicing from one centre
and applied these to all. We recorded and valued all
training, assuming that 50% of the training was given by
a specialist registrar in themiddle of the incremental pay
scale and 50% by a F grade nurse specialist.
Costs of intensive care units—Each hospital provided
the cost of a bed day in intensive care. We apportioned
the cost in relation to length of stay, rounding up stays
of less than one day to one day.
Statistical analysis
Results are given as means (standard deviations) for
normally distributed data and as medians with ranges
for non-normally distributed variables. All tests and P
values are two tailed and were analysed on an intention
to treat basis. We used t tests to compare the group
means and the Mann-Whitney U test to compare the
medians. We applied Bonferroni’s correction to multi-
ple comparisons. We used Fisher’s exact test to analyse
two by two tables. We generated Kaplan-Meier curves
for time data and used the log rank test to compare
them. We used SPSS version 9 for our analyses. We
applied non-parametric bootstrap techniques to the
cost data for deaths avoided. We report the mean costs
for 1000 bootstrap replications and assessed the
significance of negative cost effectiveness ratios by
using cost effectiveness acceptability curves.
Results
Clinical outcomes
One hundred and eighteen patients were randomised
to non-invasive ventilation and 118 to standard
treatment. The two groups had similar characteristics
on admission.5 Of the group receiving standard
treatment, 32/118 (27% (SD 8%)) met the primary
clinical end point, “need for intubation,” compared
with 18/118 (15% (SD 6.5%)) in the group receiving
non-invasive ventilation (P < 0.02).
Of the 32 patients receiving standard treatment
who met the failure criteria, only 75% (24) received
ventilatory support either invasively or non-invasively
(non-invasive ventilation alone 38% (12), non-invasive
ventilation followed by invasive mechanical ventilation
9% (3), invasive mechanical ventilation alone 28% (9)).
Eighteen patients in the non-invasive ventilation group
met the failure criteria, of whom 7 (39%) received inva-
sive mechanical ventilation. Of the standard group
24/118 (20% (SD 7.3%)) died, compared with 12/118
(10% (SD 5.5%) in the non-invasive ventilation group
(P=0.046).5 We found no statistical difference in need
for intubation or mortality between the centres.
Median length of stay in hospital was similar between
the two groups, at 10 days (range: standard group
2-119 days, non-invasive ventilation group 4-137 days,
P=0.27).
Cost data
Ward costs—Twenty five wards in 14 hospitals
participated in this study. The ratios of nurses to
patients ranged from 1:2.6 to 1:13, with a median of
1:11. Nine out of 14 centres provided detailed ward
and overhead costs, which accounted for 85% of the
patients recruited. The median cost of a bed day was
£108 (range £77 to £214). The median value was
Patients randomised (n=236)
Died
(n=24)
Survived
(n=94)
Patients allocated to
standard treatment (n=118)
Patients allocated to non-
invasive treatment (n=118)
Died
(n=12)
Survived
(n=106)
Profile of randomised controlled trial of 236 patients in 14 centres in
the United Kingdom
Interventions
Standard medical treatment (118 patients)
Controlled oxygen to maintain Spo2 at 85-90%
Nebulised salbutamol 5 mg 4-6 hourly
Nebulised ipratropium bromide 500 g 6 hourly
Prednisolone 30 mg once a day for a minimum of
5 days
Antibiotic agent
Non-invasive ventilation (118 patients)*
Bilevel positive pressure ventilation through a face or
nasal mask
Inspiratory pressure initially 10 cm H2O, increased to
20 cm H2O
Expiratory pressure 5 cm H2O
Target duration first day 24 hours, second day 16
hours, third day 8 hours, fourth day discontinued
Oxygen in the circuit to maintain Spo2 at 85-90%
*Non-invasive ventilation was given in addition to
standard treatment.
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applied to centres not providing full financial data.
Non-invasive ventilation was associated with a modest
increase in nursing workload of 26 minutes in the first
eight hours of the admission (table 1). No difference
became apparent after the first eight hours. The cost of
this additional workload was £4.45 per patient
receiving non-invasive ventilation.
Costs of intensive care centres—Ten centres admitted
patients to intensive care. The mean cost of a bed day
in intensive care was £1228 (95% confidence interval
£1052 to £1404, n=8). The median length of stay in
intensive care was similar between the standard group
(5 days, range 1 to 53 days) and the non-invasive venti-
lation group (6 days, range 2 to 15 days, P=0.38). In
intensive care, the standard group (n=12) consumed
116 bed days and the non-invasive ventilation group
(n=7) 43 bed days.
Costs of non-invasive ventilation—Table 2 shows the
equipment purchased to set up the service. Allowing a
three year lifespan for the ventilator and a two year
lifespan for the consumables generates an equivalent
annual cost of £839 and £266, respectively, at a
discount rate of 5%.8 The annual servicing cost was £26
per ventilator.
The mean amount of formal training given in the first
three months of opening a ward was 7.6 (SD 3.6)
hours. Thereafter each centre received 0.9 (SD 0.82)
hours per month. The cost of providing training was
£11-67 per hour.
The initial costs for equipment and the need for
training are fixed costs that are independent of the
number of patients treated in a centre. Additional costs
were incurred by treating an individual patient. This
included cleaning of equipment and replacement of
masks and connectors after 10 patients (£11-75 per
patient).
Where patients in the standard group were given
non-invasive ventilation after standard treatment had
failed, we assumed this treatment to have cost a 118th
of the total study costs of non-invasive ventilation
(equipment, training, and additional nursing time).
Cost effectiveness
Table 3 shows the total hospital costs in relation to
in-hospital mortality, the primary outcome for the
health economic analysis. Non-invasive ventilation was
associated with a £49 362 reduction in costs and a 50%
reduction in mortality, with an additional 12 patients
being discharged.
The main area of cost saving was in the use of
intensive care units. The cost per patient in each group
was skewed because of the high cost of patients admit-
ted to intensive care. We therefore applied non-
parametric bootstrapping to the cost data for deaths
avoided. We performed 1000 bootstrap replications,
and the mean costs were £2800 (95% confidence inter-
val £1896 to £4388) for the group receiving standard
treatment and £2155 (£1742 to £2966) for the
non-invasive ventilation group. The mean cost
difference between the treatments shows a saving of
£645 per patient receiving non-invasive ventilation
( − £2310 to £386). The results indicate that non-
invasive ventilation is a dominant strategy (more effec-
tive and less costly). However, the magnitude of
negative incremental cost effectiveness ratios is not
informative, and several problems are associated with
such confidence intervals. We generated a cost
effectiveness acceptability curve, which is used to
incorporate the uncertainty around the estimates of
mean costs and outcomes and the maximum (or
ceiling) incremental cost effectiveness ratio that the
decision maker would consider acceptable. The curve
showed an 80% probability that non-invasive ventila-
tion has a negative cost effectiveness ratio, meaning
that it is cheaper and more effective. At a ceiling cost of
£5000 per death prevented, the probability is 95% that
non-invasive ventilation is more cost effective than
standard treatment.
Table 1 Minutes of direct nursing care per patient per time period. Values are medians
(ranges)
Type of care
Time period from randomisation
0-1 hours* 1-8 hours* 8-24 hours 24-48 hours
Standard 25 (5-84) 54 (11-130) 84 (21-262) 106 (34-385)
Non-invasive ventilation 35 (7-95) 70 (19-179) 103 (32-228) 127 (30-251)
*P<0.05.
Table 3 Cost effectiveness of ward based non-invasive ventilation in reducing mortality
in hospital in two groups of patients (n=236)
Standard treatment
(n=118)
Non-invasive ventilation
(n=118)
Costs (£):
Ward 127 355 139 243
Non-invasive ventilation 3 390* 26 664
Additional non-invasive ventilation nursing 67* 525
Intensive care unit 142 576 52 981
Total 337 435 288 073
Effectiveness of intervention:
No of deaths 24 12
No discharged 98 108
Saving with non-invasive ventilation (£) — 49 362
Deaths avoided with non-invasive ventilation — 12
*Cost due to the use of non-invasive ventilation after meeting failure criteria.
Table 2 Cost of purchasing equipment for each centre
Equipment No Cost (£)
Masks:
Full face aircraft mask* 2 160.00
Small face mask† 1 75.00
Nasal mask frame 1 17.00
Small nasal mask 1 36.00
Medium nasal mask 1 36.00
Mouthpiece 1 0.75
Nose clips 1 1.00
Headgear:
Child soft cap 1 28.00
Medium soft cap 1 30.00
Large rescap 1 21.00
Chin strap 1 12.00
Connectors:
Elbow connectors 2 1.80
Hooks for aircraft mask 2 sets 1.00
Whisper swivel exhale valve 2 46.00
Oxygen port caps 2 sets 1.00
22 mm tubing 2 32.00
Masks, headgear, and connectors Total 519.55
Ventilator:
VPAPII ventilator‡ 1 2400.00
*Friday Medical, London, UK.
†Respironics, Murrysville, USA.
‡Resmed (UK) Limited, Abingdon, UK.
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Modelling
Because most costs for non-invasive ventilation are
related to fixed costs the analyses may be sensitive to
the number of patients treated in a centre. Hence we
modelled the costs and effects of providing and not
providing non-invasive ventilation in a typical hospital
in the United Kingdom (population 250 000, standard-
ised death rate for chronic obstructive pulmonary dis-
ease 100). A typical hospital will admit 72 patients per
year with respiratory acidosis (pH < 7.35 and Paco2 < 6
kPa) after immediate management.9 Fifty six will have a
pH between 7.25 and 7.35. When a three day duration
of non-invasive ventilation is assumed two ventilators
will meet the demand for these 56 patients on 99% of
days (calculated by using Poisson distribution).10
The box shows a comparison of the annual costs
and effects of providing a non-invasive ventilation
service for these 56 patients in a typical UK hospital
compared with a standard service. We modelled two
intubation rates in the standard group. In the
randomised controlled trial 75% (24) of patients failing
in the standard group received ventilatory support;
38% (12) received non-invasive ventilation alone; and
38% (12) received invasive mechanical ventilation
before or after non-invasive ventilation. Where no
non-invasive ventilation service exists only invasive
mechanical ventilation will be available; the expected
rate of invasive mechanical ventilation in a UK hospital
without non-invasive ventilation could therefore
fluctuate between 38% and 75%. The provision of a
non-invasive ventilation service generates a saving of
£12 351 per year in the setting of low rates of
intubation and £53 078 in the setting with higher rates
of intubation. This is achieved through preventing
three and nine admissions to intensive care, respec-
tively. From the hospital’s perspective the provision of
non-invasive ventilation would incur costs only if the
use of intensive care units fell by 55%.
Discussion
The health economic analysis of the randomised con-
trolled trial showed that non-invasive ventilation is a
dominant strategy from the hospital’s perspective for
patients with chronic obstructive pulmonary disease
who have mild to moderate acidosis. The procedure
reduced overall costs and reduced in-hospital mor-
tality. Dominant strategies generate negative cost effec-
tiveness ratios, which can be difficult to interpret. For
example, if an intervention generates a £1000 saving
for 10 lives (£100 saving per life saved), doubling the
effectiveness generates a figure of a £50 saving per life
saved. This seems financially less attractive but in real-
ity is a superior outcome. We therefore generated a
cost effectiveness acceptability curve to overcome the
problems of a negative cost effectiveness ratio and the
ratio’s 95% confidence interval. This indicated an 80%
probability that the non-invasive ventilation will gener-
ate a saving per life saved and a 95% probability that
each life saved will cost less than £5000.
A notable proprtion of the costs of non-invasive
ventilation are fixed costs are and therefore influenced
by throughput. We therefore modelled the analysis to
the annual needs of a typical hospital in the United
Kingdom. When we used this different method of
analysis and the 95% confidence interval for clinical
outcomes rather than the costs, non-invasive ventila-
tion was still associated with savings and a superior
clinical outcome. From the hospital’s perspective the
provision of non-invasive ventilation would incur costs
only if the use of intensive care units fell by 55%. Inter-
nationally, intubation rates in the United Kingdom are
considered low, and a further reduction to such low
levels is clinically unrealistic and would almost
certainly be associated with a higher mortality.
Moreover such a change in practice is unlikely because
of international standardisation and the development
of international and global guidelines. Although these
analyses show a saving to the hospital as a whole, costs
are increased on the respiratory wards and this should
be considered by clinicians and managers who are set-
ting up non-invasive ventilation services. However, this
cost was more than offset by the savings in costs of
intensive care units.
Cost effectiveness
The bootstrapping analyses and the modelling indicate
that our conclusions are robust and that non-invasive
ventilation is a highly cost effective intervention.We are
unaware of any similar prospective cost effectiveness
analysis of non-invasive ventilation in the ward setting.
However, in the intensive care setting non-invasive
Costs and effects of providing a non-invasive
ventilation service in a typical UK hospital
treating 56 patients per year
Non-invasive ventilation service
Ventilator and consumables: £2262
Replacement masks: £658
Training: £139
Additional nursing: £249
Annual cost: £3308
Patients admitted to intensive care unit for invasive
mechanical ventilation:
No (95% CI): 3 (2 to 5)
Cost (95% CI) of intensive care unit: £21 959
(£12 671 to £31 246)
Total cost per year with non-invasive ventilation
service: £25 267
Standard service
Low rate (38%) of invasive mechanical ventilation in
intensive care unit:
No of patients admitted: 6
Cost of intensive care unit: £37 618
High rate (75%) of invasive mechanical ventilation
in intensive care unit:
No of patients admitted: 12
Cost of intensive care unit: £78 345
Cost saving achieved by non-invasive mechanical
ventilation
Low rate (38%): £12 351 (plus 3 admissions to
intensive care unit)
High rate (75%): £53 078 (plus 9 admissions to
intensive care)
Note: Category “Ventilator and consumables”
assumes three year lifespan for ventilators and a two
year lifespan for initial consumables. Category
“Replacement masks” assumes that masks, headgear,
and connectors were replaced after 10 patients.
Category “Cost of intensive care unit” applies the
median cost of an admission to intensive care
(£6610).
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ventilation has been shown consistently to reduce the
need for intubation by between 52% and 87%,1–4 and in
the largest study of intensive care units it has also been
shown to reduce mortality by 65%.1 By using
predefined criteria our randomised controlled trial
shows a 44% reduction in the need for intubation and
a 50% reduction in in-hospital mortality,5 which
confirms the assumption of Bott et al that ward based
non-invasive ventilation can reduce mortality.11 In view
of this level of effectiveness and the large difference in
cost between care on a ward and in an intensive care
unit, it is not surprising that ward based non-invasive
ventilation has been found to be highly cost effective.
Keenan et al have conducted an economic evaluation
of non-invasive ventilation for severe acute exacerba-
tions of chronic obstructive pulmonary disease on the
basis of a theoretical model.12 This model involved
decision tree analysis constructed from a meta-analysis
of published randomised controlled trials. They too
concluded that non-invasive ventilation was a domi-
nant strategy for severe exacerbations of chronic
obstructive pulmonary disease.
International perspective
Our study must, however, be put into an international
perspective. In many European countries and in North
America non-invasive ventilation would not be consid-
ered an appropriate treatment on the ward. In the
United Kingdom, however, intensive care beds are in
short supply, and if patients with chronic obstructive
pulmonary disease are to be offered non-invasive ven-
tilation this must usually happen on the ward.
Availability of intensive care beds also explains the low
intubation rates and higher mortality found in this and
other studies from the United Kingdom.11 The features
of the UK setting may reduce both the generalisability
of the mortality data and the cost effectiveness analysis
to countries with better provision of intensive care
units. However, for the United Kingdom, non-invasive
ventilation for patients with mild to moderate acidosis
due to decompensated chronic obstructive pulmonary
disease is a highly effective technique that improves
clinical outcomes, reduces demand for intensive care,
and, from the hospital’s perspective, reduces costs.
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What is already known on this topic
Non-invasive ventilation reduces the need for
intubation and mortality in hospital in patients
with acute exacerbations of chronic obstructive
pulmonary disease and acute respiratory failure
The procedure is feasible in the ward or intensive
care environment
What this study adds
Non-invasive ventilation given on wards reduces
the need for intubation by 44% and halves
mortality in hospital in patients with chronic
obstructive pulmonary disease and mild to
moderate acidosis
The early use of non-invasive ventilation on the
ward reduces costs and improves outcomes
compared with traditional medical treatment
The main cost saving is in preventing the use of
intensive care facilities
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